Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apalutamide - Janssen Research and Development

Next Previous
Drug Profile

Apalutamide - Janssen Research and Development

Alternative Names: ARN-509; ERLEADA; Erleada; ERLYAND; JNJ-56021927; JNJ-927

Latest Information Update: 05 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aragon Pharmaceuticals; University of California
  • Developer Aragon Pharmaceuticals; Case Comprehensive Cancer Center; Dana-Farber Cancer Institute; Instituto do Cancer do Estado de Sao Paulo; Janssen Research & Development; M. D. Anderson Cancer Center; Singapore General Hospital
  • Class Antiandrogens; Antineoplastics; Aza compounds; Benzamides; Pyridines; Small molecules; Spiro compounds; Sulfhydryl compounds; Thiohydantoins
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Salivary gland cancer

Most Recent Events

  • 22 Jan 2026 Janssen Pharmaceuticals, Memorial Sloan Kettering Cancer Center, University of Michigan and Weill Medical College of Cornell University complete the phase II AASUR trial for Prostate cancer (Combination therapy) in USA (PO) (NCT02772588)
  • 22 Jul 2025 Aragon Pharmaceuticals completes a phase I/II trial for Prostrate cancer (Hormone refractory, Late stage disease) in USA (PO) (NCT01171898)
  • 13 Feb 2025 Efficacy and adverse events data from a phase III LIBERTAS trial in Prostate cancer presented at the 2025 Genitourinary Cancers Symposium (ASCO-GeCS-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top